1-866-598-7166

A Study of V940 (Cancer Vaccine) and Pembrolizumab After Surgery for Clear Cell and Papillary Kidney Cancer (INTerpath-004)

Trial ID: NCT06307431
Kidney Cancer Type: Clear cell or papillary type


Background:

Intismeran autogene (V940/mRNA-4157) is a personalized cancer vaccine made using mRNA technology, designed to help the immune system recognize and fight the patient’s specific cancer.

Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells.

 

The Trial:

This clinical trial is investigating whether adding a new mRNA cancer vaccine called intismeran autogene (also known as V940 or mRNA-4157) to the immunotherapy drug pembrolizumab (Keytruda®) can better prevent kidney cancer from coming back after surgery.

The main goal is to see if this combination helps people live longer without the cancer returning, compared to pembrolizumab with a placebo.

Participants will be randomly assigned to one of the below treatment regimes:

  • Pembrolizumab + intismeran autogene
  • Pembrolizumab + placebo

The trial is “blind”, so both you and your doctor will not know which therapy you are receiving. 

 

Basic Eligibility:

  • Clear cell renal cell carcinoma (ccRCC) or papillary type.
  • You have had surgery to remove the kidney tumor (partially or fully removed kidney)
  • Your cancer is considered intermediate to high risk.

 

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreBC Cancer Principal InvestigatorNot Given LocationVancouver, BC Trial StatusActive, Not Recruiting
Hospital / Cancer CentreCHU de Québec Principal InvestigatorNot Given LocationQuébec, QC Trial StatusActive, Not Recruiting
Kidney Cancer Canada